Scandinavian ChemoTech
2.19 SEK -1.79%Be the first to follow this company
Scandinavian ChemoTech is a research and development company that has developed the technology Tumor-Specific Electroporation - TSE ™ for the treatment of various cancers. The technology means that electronic pulses are sent to the treated area and the membranes of the tumor cells are opened to reach their DNA. In addition to its operations in Sweden, the company is also active in Southeast Asia and India. Scandinavian ChemoTech was founded in 2015 and is headquartered in Lund.
Revenue
2.82M
EBIT %
-717.73 %
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
CMOTEC B
Daily low / high price
2 / 2.41
SEK
Market cap
39.28M SEK
Turnover
20.46K SEK
Volume
9.5K
Financial calendar
Interim report
07.05.2024
General meeting
14.05.2024
Interim report
13.08.2024
Interim report
05.11.2024
Annual report
04.03.2025
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Försäkringsbolaget Avanza | 13.3 % | 11.2 % |
Mohan Frick (privat och genom bolag) | 12.1 % | 20.2 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
ChemoTech obtain approval of the third and last patent application in India
ChemoTech attains progress by obtaining patent protection for two essential patents in India
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools